Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ

Similar documents
Symposium. Post-operative Management Of Pediatric Heart Transplantation : A Brief Review

9/30/ DISCLOSURES. + First: Why immunosuppress? Transplant Immunosuppression and Prophylaxis

Emerging Drug List EVEROLIMUS

OBJECTIVES. Phases of Transplantation and Immunosuppression

Complications of VAD therapy - RV failure

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017

Medications in the Solid Organ Transplant Recipient

BK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy

Overview of New Approaches to Immunosuppression in Renal Transplantation

Certified Clinical Transplant Nurse (CCTN) * Detailed Content Outline

INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION a Society that includes Basic Science, the Failing Heart, and Advanced Lung Disease

DEMYSTIFYING VADs. Nicolle Choquette RN MN Athabasca University

Considering the early proactive switch from a CNI to an mtor-inhibitor (Case: Male, age 34) Josep M. Campistol

2/28/2017. Adult Heart Transplants Donor and Recipient Characteristics UNOS, Retransplant VCM. Other /2015 (N = 24,474)

Evaluation of a Weight-based Rabbit Anti-thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients

Efficacy and Safety of Thymoglobulin and Basiliximab in Kidney Transplant Patients at High Risk for Acute Rejection and Delayed Graft Function

European Risk Management Plan. Measures impairment. Retreatment after Discontinuation

Steroid-Free Maintenance Immunosuppression After Heart Transplantation

Management of Cardiogenic Shock. Dr Stephen Pettit, Consultant Cardiologist

Nephrology Dialysis Transplantation

Induction Immunosuppression With Rabbit Antithymocyte Globulin in Pediatric Liver Transplantation

UNIVERSITY OF NORTH CAROLINA HOSPITAL SCUT MONKEY PROTOCOL FOR ABDOMINAL TRANAPLANT SERVICE Revised June 2013

Heart Transplantation

Immunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Marta Farrero Torres₁, Marcelo Pando₂, Dolly Tyan₂, Hannah Valantine₃, Spenser Smith₃, Kiran Khush₃

Heart Transplant: State of the Art. Dr Nick Banner

Nephrology Grand Rounds

Childhood Primary Central Nervous System Vascultis Treatment Protocols

Intruduction PSI MODE OF ACTION AND PHARMACOKINETICS

Research Article The Natural History of Biopsy-Negative Rejection after Heart Transplantation

Postoperative monitoring after

Clinical decisions regarding immunosuppressive

Twenty-Year Survivors of Heart Transplantation at Stanford University

Alemtuzumab Induction in Non-Hepatitis C Positive Liver Transplant Recipients

06/04/2013 ISHLT. 2 International Conference on Respiratory Physiotherapy ARIR Genova, March 21 23, 2013

RESULTS previously reported from this center

NAPRTCS Annual Transplant Report

3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial

Mechanical Cardiac Support and Cardiac Transplant: The Role for Echocardiography

Long-term outcomes after 1000 heart transplantations in six different eras of innovation in a single center

Targeted Adverse Event (ADV)

Solid Organ Transplantation 1. Chapter 55. Solid Organ Transplant, Self-Assessment Questions

Transplantation in Australia and New Zealand

Index. Note: Page numbers of article titles are in boldface type.

Liver Transplant Immunosuppression

This study is currently recruiting participants.

Controversies in Renal Transplantation. The Controversial Questions. Patrick M. Klem, PharmD, BCPS University of Colorado Hospital

University of Florida Department of Surgery. CardioThoracic Surgery VA Learning Objectives

SINCE the introduction of Imuran and

Chronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.

Nothing to Disclose. Severe Pulmonary Hypertension

NAPRTCS Annual Transplant Report

The 1-year survival rate approaches 80% for patients

What is the Best Induction Immunosuppression Regimen in Kidney Transplantation? Richard Borrows: Queen Elizabeth Hospital Birmingham

Jennifer A. Brown The Cleveland Clinic School of Perfusion Cleveland, Ohio

Childhood Primary Central Nervous System Vascultis Treatment Protocols

Extra Corporeal Life Support for Acute Heart failure

By the way, I have a transplant..

Intra-operative Effects of Cardiac Surgery Influence on Post-operative care. Richard A Perryman

Glossary. Anesthesiologist A doctor who puts you or parts of your body to sleep during surgery.

I topic liver transplantation (OLT) to avoid organ

LONG-TERM RESULTS OF CARDIAC TRANSPLANTATION IN PATIENTS OLDER THAN SIXTY YEARS

Heart Transplantation is Dead

BK Virus (BKV) Management Guideline: July 2017

Transplant in Pediatric Heart Failure

Solid Organ Transplant

Immunosuppression: evolution in practice and trends,

MODERATOR Felix Rapaport, other members of this

2017 CST-Astellas Canadian Transplant Fellows Symposium. Management of Renal Dysfunction in Extra Renal Transplants

Immunosuppressant medicines have allowed patients

REACH Risk Evaluation to Achieve Cardiovascular Health

ASSESSMENT OF THE PAEDIATRIC NEEDS IMMUNOLOGY DISCLAIMER

Disclosures. ICU Management of Advanced Lung Disease 5/9/2015. No Disclosures. All pictures from commercial sources

Heart Transplantation for Patients with a Fontan Procedure

Intra-operative Echocardiography: When to Go Back on Pump

Renal Transplant. Tony Chacon. Program Head BCIT Nephrology Nursing Program.

Human Heart Transplantation: Current Status

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011

Better than Google- Click on Immunosuppression Renal Transplant. David Landsberg Oct

Wound Healing Complications with De Novo Sirolimus Versus Mycophenolate Mofetil-Based Regimen in Cardiac Transplant Recipients

FUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART

Definitions. You & Your New Transplant ` 38

Aljoša Kandus Renal Transplant Center, Department of Nephrology, University Medical Center Ljubljana, Slovenia

Tolerance Induction in Transplantation

Fellows Conference 01/21/2016

Scottish Medicines Consortium

Transplant Hepatology

Cyclosporin A in Cardiac Transplantation: Medium-term Results in 62 Patients

Cover Page. The handle holds various files of this Leiden University dissertation.

Thymoglobulin induction dosing strategies in a low-risk kidney transplant population: Three or four days?

Cardiac surgery - CAD

Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients

Recognition and Treatment of Chronic Allograft Dysfunction

ORIGINAL ARTICLE. Alexander M. Bernhardt a, *, Theo M.M.H. De By b, Hermann Reichenspurner a and Tobias Deuse a. Abstract INTRODUCTION

ino in neonates with cardiac disorders

Literature Review: Transplantation July 2010-June 2011

Post Transplant Immunosuppression: Consideration for Primary Care. Sameh Abul-Ezz, M.D., Dr.P.H.

Cases: CMV, HCV, BKV and Kidney Transplantation. Simin Goral, MD University of Pennsylvania Medical Center

A Tolerance Approach to the Transplantation of Vascularized Tissues

Transcription:

Post Operative Management in Heart Transplant นพ พ ชร อ องจร ต ศ ลยศาสตร ห วใจและทรวงอก จ ฬาลงกรณ

Art of Good Cooking Good Ingredient Good donor + OK recipient Good technique Good team Good timing Good organization Well practice

Heart Transplant: Peri-op Issues Donor Surgical techniques Peri operative graft Failure Imm-suppressive and rejection management Renal function management

Issues: medium long term Renal function management Transplant Allograft Vasculopathy Malignancy CMV infection

Donor Management Matching Donor cardiovascular care Donor procurement and preservation

Donor Cardiovascular Care Minimize effects of brain dead physiology DI Hormone Vascular tone Fluid+ Electrolyte deranged Over Innotropic drug Low Hct Low plasma osmolarity

Donor-recipient Matching Size: Greater than 80% of recipient body weight Blood type: Identical or compatible HLA-matching: Generally not done Direct X match only in preformed antibody found in recipient

Donor Procurement and Preservation Preservative agent St Thomas Cardioplegia Blood Cardioplegia Celsior HTK solution Custodiol

Donor Procurement and Preservation Ischemic Time Optimum time : less than 4 hours Acceptable to 6 hours On arrival blood cardioplegia technique in long ischemic time case

Surgical Techniques

Surgical Complications Bleeding Mal alignment Flow obstruction Tricuspid regurgitation

Immediate Post Op Complications Pumping failure Renal failure Rejection Bleeding

Pumping Failure Graft preservation and Ischemic time Hyper acute rejection Acute rejection Right heart failure Pulmonary hypertension?

Right Side Heart Failure Most common cause of death in peri operative Right ventricle is more prone to ischemic injury Thin wall - less reserve muscle contraction Room temperature exposed

Right Heart Failure High CVP Distended Rt ventricle Tricuspid regurgitation High Pulmonary artery pressure(pap) +/- Low PAP but distended RV very bad sign

Treatments of RV Failure Decompress right side Optimal preload volume Over fill increases Tricuspid regurgitation Lower Pulmonary vascular resistance Maximum ventilation support Drugs : NTG, Isuprel, Primacor, Viagra Nitric Oxide, Illoprost Increase RV contraction Mechanical support : IABP Ventricular assist device

Left Side Failure Mostly from donor heart issues Donor pre transplant condition Ischemic time Myocardium Preservation Acute rejection is rare Mostly result of reperfusion injury

Treatments of LV Failure Rest myocardium : Empty beating heart Optimal innothropic drugs Optimal environment for myocardium recovery Preload / Afterload Blood gas, Electrolyte, acid base,calcium etc Mechanical Support IABP VAD

Ventricular Assist Device

Bi Ventricular (a) Cannulation for CentriMag Assist BiVAD Device Takayama H. et al.; Interact CardioVasc Thorac Surg 2011;12:110-111

Rejection

Immunosuppressive Therapy CNI Cyclosporine A FK 506 Antimetabolite Azathioprine Mycophenolate Steroid Adrenocortical steroids Lymphocytolytic Therapy Anti-thymocyte globulin (ATG)

Induction Therapy RATG: Reduce Acute rejection Periop acute renal failure Long term rejection Increase Infection

Standard Triple therapy Preoperative Azathioprine: 4 mg/kg IV Intraoperative Methylprednisolone: 500 mg Postoperative Cyclosporine: 2-6 mg/kg po bid based on trough levels and renal function Azathioprine: 2 mg/kg/day Methylprednisolone: 125 mg IV every 8 hours for 3-4 doses, followed by prednisone Prednisone: (beginning after Methylprednisolone)1 mg/kg/day tapering over 1 week to 0.5 mg/kg/day,

Maintenance Immunosuppression Goal Lowest overall level of immunosuppression to prevent rejection Cyclosporine levels Low therapeutic after 1-2 years Azathioprine 1-2 mg/kg/day after 1-2 years Prednisone 0-0.1 mg/kg/day after 1 year

Problem with CNI Renal toxicity esp during critical period Injured and recovering myocardium Injured renal after CPB Compromised cardiac output and renal perfusion

CNI free Regimens m TOR inhibitor Sirolimus (Rapamune) Everolimus (Certican) No renal toxicicty Higher rate of rejection in de novo used.

Strategies :Renal Shutdown Immediate Post Op Prolonged Induction Higher rate of infection CNI free regimen de novo Higher rate of rejection Lower CNI combined with mtor Forget kidneys and protect heart Renal transplant after kidney transplant?

Rejection Endomyocardial biopsy Acute rejeciton Hospital Out-patient

Rejection

Rejection

Rejection

TREATMENT OF REJECTION GRADE Mild Moderate Moderate Severe None or oral corticosteroid augmentation Oral corticosteroid augmentation or IV corticosteroids IV corticosteroids +/- ATG or OKT3

Infection Most of fatal infection in post op heart transplant came from Colonized pre transplant (poor condition recipient) Consequences of prolong postop heart failure; prolong intubation CMV is the most common infection problem in medium and long term

Infection Pre transplant prolong intubation is the most important risk factor in post transplant infection Prolong post transplant intubation must be avoid Post op renal failure contribute to fatal infection

Infection Bacterial - Most Common Viral Fungal

Infectious Prophylaxis Pathogenic Organism Cytomegalovirus Herpes simplex Toxoplasmosis Pneumocystis Oral candidiasis Prophylactic Agent Gancyclovir, Acyclovir, IVIg Acyclovir Pyrimethamine and Leucovorin TMP/SMX, Dapsone, Pentamidine Nystatin, Mycelex troches

Peri operative Renal Failure Poor renal perfusion Poor cardiac function Post cardio pul bypass injury CNI toxicity in not fully recovered renal Induction Therapy : give renal toxic free window period

Renal Failure Most important side effect of cyclosporin from afferent arteriolar vasoconstriction and direct tubular cell injury; Dose related to some extent and will improve with reduction in the Cyclosporin dose

Peri operative renal failure Extended induction technique Intermittent RATG after complted normal induction duration Follow CD 3 CNI free until renal recover Significantly increase infection

Common Dilemmas Poor cardiac function Cannot extubate Cannot start oral CNI Prolong use of RATG : over suppress Infection flare up

Common Dilemmas Poor cardiac function Poor urine flow Cannot start oral CNI Higher risk of rejection

Conclusions Donor recipient condition Most important Right side heart failure is the most common cause of operative dead Prolong poor cardiac function leaded to prolong intubation and fatal infection Post operative care is the most difficult aspect in heart transplant

Thank you